Evidence map›Paper›PMID 33709285›Full record

ArticleDrug delivery and translational research2022

Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier.

Ana Isabel Oliveira, Cláudia Pinho, Bruno Sarmento, Alberto C P Dias

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ana Isabel OliveiraCentro de Investigação Em Saúde E Ambiente (CISA), Escola Superior de Saúde -Politécnico do Porto (ESS-P.Porto), 4000-072, Porto, Portugal. aio@ess.ipp.pt.ORCID http://orcid.org/0000-0003-4420-6476
Cláudia PinhoCentro de Investigação Em Saúde E Ambiente (CISA), Escola Superior de Saúde -Politécnico do Porto (ESS-P.Porto), 4000-072, Porto, Portugal.
Bruno Sarmentoi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal.
Alberto C P DiasCentre of Molecular and Environmental Biology (CBMA), Biology Department, Department of Biology, University of Minho, 4710-057, Braga, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Search for efficient therapeutic agents for central nervous system (CNS) disorders has been extensive. Nevertheless, blood-brain barrier (BBB) is an obstacle that prevents the majority of compounds to act in these diseases. It is, thus, of extreme relevance the BBB overcome, in order to deliver a drugs therapeutically active concentration to the action site, with the least losses and interaction with other organs, tissues, or cells. The present study aimed to investigate the potential protective effect of quercetin-biapigenin encapsulated into poly(Ɛ-polycaprolactone) (PCL) nanoparticles against t-BOOH-induced oxidative stress in several brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro BBB model. The three cell lines under study (BV-2, hcmec/D3, and U87) presented different reactions to t-BOOH. In general, quercetin-biapigenin PCL-loaded nanoparticles were able to minimize compound toxicity they convey, regardless the cell line. Quercetin-biapigenin PCL-loaded nanoparticles (Papp of approximately 80 × 10-6 cm/s) revealed to be more permeable than free compounds (Papp of approximately 50 × 10-6 cm/s). As of our knowledge, this is the first report of quercetin-biapigenin PCL-loaded nanoparticle activity in brain cells. It is also the first determining its permeability through BBB, as an effective nanocarrier for brain delivery.

Indexed as

Blood-Brain BarrierNanoparticlesApigeninBiflavonoidsQuercetinApigeninbiapigeninBiflavonoidsQuercetinBiapigeninNanoparticlesNeuroprotectionPermeabilityPoly(ɛ-polycaprolactone)Quercetin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.